Long-Term Impact of Peritoneal Dialysis Ultrafiltration on Cardiorenal Patients
Cardiorenal Medicine · 2025
DOI: 10.1159/000546924 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiorenal Medicine, 2025. Verfasst von Sara Núñez-Delgado und 8 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Vall d'Hebron University Hospital, Nephrology and Transplantation group, Vall d'Hebron Research Institute, Barcelona, Spain. Hauptthemen laut MEDLINE: Peritoneal Dialysis, Cardio-Renal Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Heart failure (HF) prevalence is increasing, and its prognosis worsens in the presence of other comorbidities. Up to 70% of patients develop cardiorenal syndrome (CRS), which is associated with diuretic resistance or kidney deterioration over time. Peritoneal dialysis (PD) for ultrafiltration (PD-UF) could be a potential therapeutic option in CRS, although its long-term outcomes have not been described.
Methods
Retrospective registry study of the Catalan Renal Registry on patients with PD-UF indication between 2013 and 2022. Baseline clinical characteristics and follow-up until December/2022 was studied.
Results
Of the 1,874 incident patients on PD, 198 (10.6%) were PD-UF, 73.2% of the patients were male, and the mean age was 70.7 ± 9.3 years. Median estimated glomerular filtration rate (eGFR) at start was 22.6 (IQR: 14.8–32.8) mL/min×1.73 m2 and 75.0% have an eGFR above 15 mL/min×1.73 m2. Previous history of ischemic heart disease, arrhythmia, or cardiac surgery was recorded, and 57.6% of patients had ≥2 of these pathologies. The most common HF etiology was ischemic heart disease in 21.7% of patients. Median overall patient survival was 21 (IQR: 17.3–24.3) months. Technique survival at 1 year was 94.8%, and 27 patients were transferred to other renal replacement therapy (hemodialysis or kidney transplantation). In the Cox multivariate analysis, age ≥75 years (HR: 1.76 [95% CI: 1.20–2.59]), mild frailty (HR: 2.18 [95% CI: 1.17–2.59]), severe frailty (HR: 17.62 [95% CI: 1.20–55.48]), and the burden of cardiac disease (2 categories HR: 2.17 [95% CI: 1.05–4.47]; 3 categories HR: 2.26 [95% CI: 1.05–4.89]) were associated with poor overall survival. Technique survival was associated with eGFR (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nephrology Department, Vall d'Hebron University Hospital, Nephrology and Transplantation group, Vall d'Hebron Research Institute, Barcelona, Spain.
- Cardiology Department, Vall d'Hebron Hospital, Barcelona, Spain.
- Catalan Transplantation Organization, Barcelona, Spain.
- Nephrology Department, Hospital de Sant Joan Despí Moisès Broggi - Consorci Sanitari Integral, Barcelona, Spain.
Zitieren
APA
Núñez-Delgado, S., Azancot, M. A., Méndez Fernandez, A. B., León-Román, J., Ramos Terrades, N., Toapanta, N., Comas, J., Sánchez-Escuredo, A., & Soler, M. J. (2025). Long-Term Impact of Peritoneal Dialysis Ultrafiltration on Cardiorenal Patients. Cardiorenal Medicine. https://doi.org/10.1159/000546924
Vancouver
Núñez-Delgado S, Azancot MA, Méndez Fernandez AB, León-Román J, Ramos Terrades N, Toapanta N, et al. Long-Term Impact of Peritoneal Dialysis Ultrafiltration on Cardiorenal Patients. Cardiorenal Medicine. 2025. doi:10.1159/000546924
BibTeX
@article{NezDelgado2025,
author = {Núñez-Delgado, Sara and Azancot, Maria Antonieta and Méndez Fernandez, Ana Belén and León-Román, Juan and Ramos Terrades, Natalia and Toapanta, Néstor and Comas, Jordi and Sánchez-Escuredo, Ana and Soler, María José},
title = {Long-Term Impact of Peritoneal Dialysis Ultrafiltration on Cardiorenal Patients},
journal = {Cardiorenal Medicine},
year = {2025},
doi = {10.1159/000546924}
}
EUVIMED